Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer

详细信息    查看全文

• 作者：Jinwan Wang ; Ruihua Xu ; Jian Li ; Yuxian Bai ; Tianshu Liu ; Shunchang Jiao…
• 关键词：Advanced gastric cancer ; Modified docetaxel and cisplatin plus fluorouracil regimen ; Progression ; free survival ; Overall survival ; Safety
• 刊名：Gastric Cancer
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：19
• 期：1
• 页码：234-244
• 全文大小：1,133 KB
• 参考文献：1.Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535–47.PubMed CrossRef
  2.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMed CrossRef
  3.Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37–41.PubMed CrossRef
  4.Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587–91.PubMed PubMedCentral CrossRef
  5.Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.PubMed CrossRef
  6.Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R, et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60:1449–72.PubMed CrossRef
  7.Chen XL, Chen XZ, Yang C, Liao YB, Li H, Wang L, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e60320.PubMed PubMedCentral CrossRef
  8.Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3205–9.PubMed CrossRef
  9.Tomasello G, Chiesa MD, Buti S, Brighenti M, Negri F, Rovere RK, et al. Dose-dense chemotherapy in metastatik gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen. Tumori. 2010;96:48–53.PubMed
  10.Ben Aharon I, Purim O, Kundel Y, Brenner R, Gordon N, Sulkes A. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience. Anticancer Drugs. 2012;23:313–20.PubMed CrossRef
  11.Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, et al. Split-dose docetaxel, cisplatin and leucovorin/luorouracil as first line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18:1673–9.PubMed CrossRef
  12.Park SR, Chun JH, Kim YW, Lee JH, Choi IJ, Kim CG, et al. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol. 2005;28:433–8.PubMed CrossRef
  13.Chi YHBL, Ren JH, Yang L, Cui CX, Li JL, Wang JW. Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma. Chin Med J. 2011;124:2997–3002.PubMed
  14.Inal A, Kaplan MA, Kucukoner M, Isikdogan A. Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Neoplasma. 2012;59:233–6.PubMed CrossRef
  15.Ozdemir NY, Abali H, Oksuzoglu B, Budakoglu B, Uncu D, Guler T, et al. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol. 2010;27:680–4.PubMed CrossRef
  16.Kang SH, Kim JI, Goh PG, Hwang SW, Kwon DS, Nam KW, et al. Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer. Korean J Gastroenterol. 2007;50:157–63.PubMed
  17.Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;102:475–81.PubMed PubMedCentral CrossRef
  18.Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer (Phila). 2010;116:1446–53.CrossRef
  19.Keskin S, Yıldız I, Sen F, Aydogan F, Kilic L, Ekenel M, et al. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). Clin Transl Oncol. 2013;15:403–8.PubMed CrossRef
  20.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMed CrossRef
  21.National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. http://​ctep.​cancer.​gov/​protocolDevelopm​ent/​electronic_​applications/​docs/​ctcaev3.​pdf . Accessed 7 Oct 2014.
  22.Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel (Taxotere®) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer. 1994;70:380–3.PubMed PubMedCentral CrossRef
  23.Einzig AI, Neuberg D, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 1996;13:87–93.PubMed CrossRef
  24.Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMed CrossRef
  25.Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140:319–28.PubMed PubMedCentral CrossRef
  26.Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.PubMed CrossRef
  27.Lordick F, Siewert JR. Perioperative Chemotherapie vs. alleinige Chirurgie bei resektablen gastroösophagealen Karzinomen. Chirurg. 2006;77:1166–7.PubMed CrossRef
  28.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2007. http://​www.​fda.​gov/​downloads/​Drugs/​Guidances/​ucm071590.​pdf . Accessed 8 Dec 2014.
  
• 作者单位：Jinwan Wang (1)
  Ruihua Xu (2)
  Jian Li (3)
  Yuxian Bai (4)
  Tianshu Liu (5)
  Shunchang Jiao (6)
  Guanghai Dai (6)
  Jianming Xu (7)
  Yunpeng Liu (8)
  Nanfeng Fan (9)
  Yongqian Shu (10)
  Yi Ba (11)
  Dong Ma (12)
  Shukui Qin (13)
  Leizhen Zheng (14)
  Weichang Chen (15)
  Lin Shen (3)
  
  1. Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
  2. Sun Yat-Sen University Cancer Center, Guangzhou, China
  3. Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No 52 Fu Cheng Road, Haidian District, Beijing, 100142, China
  4. Harbin Medical University Cancer Hospital, Harbin, China
  5. Fudan University Affiliated Zhong Shan Hospital, Shanghai, China
  6. Chinese PLA General Hospital, Beijing, China
  7. 307 Hospital of PLA, Beijing, China
  8. The First Hospital of China Medical University, Shenyang, China
  9. Fujian Provincial Cancer Hospital, Fuzhou, China
  10. Jiangsu Provincial Hospital, Nanjing, China
  11. Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
  12. Guangdong General Hospital, Guangzhou, China
  13. PLA Cancer Center of Bayi Hospital, Nanjing, China
  14. Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
  15. Suzhou University Affiliated First Hospital, Suzhou, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Gastroenterology
  Surgical Oncology
  Pathology
  Radiotherapy
  
• 出版者：Springer Japan
• ISSN：1436-3305

文摘

Background The V325 study showed that docetaxel, cisplatin, and fluorouracil (DCF) prolonged overall survival (OS) of patients with advanced gastric cancer, but with a high incidence of dose-limiting toxicities. We investigated the efficacy and safety of a modified DCF (mDCF) regimen for Chinese patients with advanced gastric cancer.